Introduction
Bone marrow consists of a complex mixture of stromal cells that create an inductive microenvironment necessary for maintenance, proliferation, and differentiation of hematopoietic stem cells (1) (2) (3) . Long-term bone marrow cultures have been used to study stem cell regulation and reproduce the heterogeneous stromal population of endothelial fibroblasts, adipocytes, and macrophages in vitro (4, 5) . In addition, marrow stromal cells enriched with a specific antibody (Stro-1) were found to support hematopoiesis in vitro (6) . Preformed, fresh marrow-derived stromal monolayers have also been used to quantitate human stem cells in vitro (7, 8) . Although stem cells are known to home to and adhere to stromal cells in vivo and in vitro, the mechanisms by which stem cells are restricted within specific areas in the marrow remain undefined (9, 10) . Recent attention has begun to focus on the role of glycoproteins and integrins in this process (9) (10) (11) (12) (13) (14) .
Members of the integrin family of cell adhesion receptors mediate both cell-extracellular matrix and cell-cell adhesion and are involved in cell migration and localization during embryonic development, tissue organization, cell differentiation, inflammation, and metastasis (15) (16) (17) (18) (19) . The integrin family consists of at least 17 distinct heterodimers formed by associations between 13 a subunits and 7 different ,3 subunits, each with distinct ligand binding properties ( 15) . Among integrins, the VLA-5 (a5I,) complex is widely distributed and functions as a receptor for fibronectin (20, 21 ). In contrast, the VLA-4 (a4#13) complex is expressed at substantial levels on normal peripheral blood B and T cells, thymocytes, monocytes, and some melanoma cells as well as on marrow blast cells and erythroblasts (1 1, 17, 22, 23) . Ligands for VLA-4 are vascular cell adhesion molecule-I (VCAM-1 ), ' identified on the surface of activated endothelial cells (24) (25) (26) (27) and CS-1, an alternately spliced domain within the Hep II region of fibronectin (28) (29) (30) . Another group of integrins (CD1 la/CD 18, CD 1 lb/ CD1 8, and CDl lc/CD1 8) share the common f2 chain and are variably expressed on peripheral T cells, monocytes, and mature granulocytes. Ligands for 132-integrins include members of the Ig superfamily (ICAM-1 and ICAM-2) found on activated endothelial cells ( 19, 31, 32) .
Recently, we have demonstrated the role of tissue-specific adhesion protein hemonectin in mediating adhesion ofmurine colony-forming cells with a high proliferative potential (33) . In other studies, formation of day 12 colony-forming unit-spleen (CFU-s) by murine stem cells was inhibited by antibodies against integrin fl, subunit ( 13) . In addition, lymphopoiesis in murine long-term marrow cultures was inhibited and myelopoiesis retarded by addition of an anti-ca4 antibody ( 14) . Adhesion of human erythroid progenitors to fibronectin is mediated by the integrins VLA-4 and VLA-5 ( 11) whereas adhesion of human B cell precursors to marrow stroma is mediated by VLA-4 to VCAM-1 (34) . In addition, for human progenitors the adhesion molecules thrombospondin and heparan sulfate have also been implicated (35, 36) . Although VLA-4 has been detected on immature blast cells and CDlla/CD 18 found on a subpopulation of CD34+CD33-cells, their role in mediating the interaction between human stem cells and underlying stroma remains to be defined (22, 37) .
In the present study we used human CD34hI progenitors that have marrow repopulating ability together with cultured human marrow stromal cells capable of supporting hematopoiesis in an in vitro model to investigate the role ofintegrins in human stromal cell interaction with stroma.
Methods
Bone marrow cells. Normal human marrow cells were obtained from informed and consenting allogeneic bone marrow transplant patients and patients undergoing total hip replacement. Cells separated on Ficoll-Hypaque (1.077 g/dl) were added to primed polystyrene devices (Applied Immune Sciences, Menlo Park, CA) coated with soybean agglutinin (SBA). After I h of incubation the cells in the suspension (SBA-fraction, which contained -80% lineage committed progenitors) were harvested, washed, and added to flasks coated with anti-CD34 monoclonal antibodies (clone ICH3). The CD34' cells were recovered after 1 h of incubation by positive selection (38 [50] ); P3 (isotype matched negative control [51] ); anti-CD34 (Amac Inc., Westbrook, ME); anti-CD33PE; and anti-CD71FITC (Becton Dickinson Immunocytometry systems, San Jose, CA). Plasma fibronectin was purchased from Telios Pharmaceuticals, San Diego, CA. The FN-40 (heparin II-binding domain) fragment from fibronectin was prepared as previously described (30) . Recombinant soluble VCAM-I (sVCAM-I) was a gift from Dr. R. Lobb (Biogen Inc., Cambridge, MA). The latter was prepared by genetic alteration of the native molecule such that the transmembrane and the cytoplasmic regions are deleted (52) .
Cell surface iodination and immunoprecipitation. Stromal cells and CD34' were surface-labeled with 1251I using lactoperoxidase and lysed with 0.5% Nonidet P-40 (NP-40) in PBS containing 1 mM PMSF, 8 mM iodoacetamide, 10 IM leupeptin, 1 U/ml aprotinin. Lysates were precleared as previously described (53), specific antibodies were added, and the immune complexes harvested with Protein A-Sepharose and washed thrice with PBS containing 0.1% Triton and 0.02% SDS. Samples were analyzed on 8% SDS-PAGE as previously described (53) .
Adhesion assays. For adhesion to stromal monolayers, suspended cells were labeled by incubation in complete media with 50-150 ,uCi/ ml 5"Cr for 4 h and then washed once in PBS containing 0.5 mM EDTA and once in 0.1% BSA in RPMI, and finally were resuspended in the same solution. Labeled cells at a concentration of3-5 X I04 were added to the stromal monolayer in 96-well microtiter plates, which had been previously incubated for 24 h in complete medium, alone, or with 50 pg/ml IL-I (R&D Systems, Inc., Minneapolis, MN). After 25 min of incubation at 37°C, nonadherent cells were removed by washing three times with 0.1 % BSA in RPMI. The bound cells were then lysed in NaOH/SDS solution and the radioactivity was analyzed in a gamma counter.
For assays of CD34hi cell adhesion to purified ligands, 96-well microtiter plates (Flow Laboratories, Inc., McLean, VA) were first incubated with sVCAM-I, FN-40, or fibronectin in 0.1 M NaHCO3, pH 8.3, for 16 h at 4°C, and then for 2 h at 37°C. Next, 0.1 % BSA in 0.1 M NaHCO3, pH 8.3, was added for 2 h at 37°C to block nonspecific adhesion. Cells were labeled in complete media by incubation with 50 1sCi/ml 5'Cr for 4 h and washed and resuspended as described for adhesion to stroma monolayers. After cells (3-5 x 104) were incubated for 25 min at 37°C with the ligand-coated microtiter plates, wells were washed thrice with 0.1 % BSA in RPMI to remove unbound cells. Remaining adhered cells were lysed and radioactivity was analyzed in a gamma counter anti-mouse antibodies. Cells that were stained for two-color fluores-cence were incubated with the second antibody which followed sequentially by biotin-conjugated anti-mouse antibodies and strepavidin-PE. Each incubation was at 4VC for 30 min and followed by two washes with PBS. Finally, immunofluorescently labeled cells were fixed in 1.5% paraformaldehyde for 10 min, washed, and resuspended in PBS. Single and two-dimensional flow cytometric analysis was performed on a FACscan (Becton-Dickinson & Co., Mountain View, CA).
Detection of growth factor mRNA by polymerase chain reaction (PCR). Total cellular RNA was prepared according to Huang and High (54) . 1 ,ug of total RNA was reverse-transcribed to cDNA using MMLV-RT and subsequently amplified using specific primers for human IL-3, IL-6, and IL-l purchased from Clonetech Laboratories, Palo Alto, CA. Both reverse transcription and amplification were done using the GeneAmp RNA PCR kit (Perkin Elmer Cetas Corp., Norwalk, CT) according to the manufacturer's recommendation.
Immunohistochemical detection of IL-la. Confluent cultures of stromal cells grown on coverslips were fixed with 3% paraformaldehyde in PBS for 5 min, washed three or four times and incubated with 1:10 dilution ofanti-IL-la (Oncogene Science, Inc., Manhasset, NY). This was followed by biotin-labeled rabbit anti-mouse secondary antibody, strepavidin-linked alkaline phosphatase, and developed with fast red substrate according to the manufacturers directions (BioGenix Labs, San Ramon, CA) and counterstained with Mayer's hematoxylin (Sigma Chemical Co., St. Louis, MO).
Results
Expression off, and IB2 integrins on CD34' cells. To determine co-expression of integrins on enriched CD34+ human hematopoietic cells, dual-color immunofluorescence staining was done (Fig. 1 ). Cells were stained with anti-CD34-FITC and antibodies to a and 3 subunits of the integrin family. Of the cells expressing CD34, 77% co-expressed VLA-4, < 3% oftotal cells expressed VLA-4 but not CD34, and -9% ofthe populaFluorescence Intensity tion expressed CD34 but not VLA-4 ( Fig. 1 A) . In cell surface iodination and immunoprecipitation experiments, anti-a 4 antibodies co-immunoprecipitated the a4 and l3I subunits indicating that CD34h1 cells express the VLA-4 complex (data not shown). Similarly, 49% of total cells co-expressed CD34 and VLA-5, < 2% of the population expressed VLA-5 but not CD34, whereas 32% of cells expressed CD34 but not VLA-5. (Fig. 1 B) . The VLA-1, VLA-2, and VLA-3 complexes were not co-expressed on CD34h' population (data not shown). The common 3 , B and #2 chains were expressed on 92.6±5% and 80±6.5%, respectively, of enriched CD34'I cells (Fig. 1, C and D). Primitive hematopoietic progenitors ( 1-3% of total marrow cells) have been described as those that do not bind to SBA, express high levels ofCD34, form blast colonies with high plating efficiency, and are enriched in long-term culture-initiating cells (LTC-IC [8] ). To determine whether our CD34+ population was enriched for primitive stem cells, their functional properties were evaluated. The CD34+ cells were incubated for 14 d in culture medium at indicated cell densities and then plated in methylcellulose with a cocktail ofgrowth factors (hrIL-3, SF, and EPO). The enriched CD34+ cells formed blast colonies with a 20-30% plating efficiency (Table I ). In addition as seen in Fig. 2 density, 20-30% expressed low densities of CD33, and < 20% expressed low densities of CD7 1 (Fig. 1, F-H (56, 57) . To determine the contribution ofa specific stromal cell subtype toward stem cell adhesion and maintenance, homogeneous fibroblast-like, stromal cell cultures devoid of macrophages were established from human marrow. As shown in Table I , these cultured stromal cultures could support proliferation ofcocultivated CD34h1 cells for up to 5 wk. In separate experiments these stromal cells also supported production of progenitors and mature hematopoietic cells from cocultivated CD34hi population (Fig. 2) .
Expression of VCAM-1, a ligand for VLA-4 was analyzed by iodination and immunoprecipitation of cell surface proteins. VCAM-1 was expressed on resting stromal monolayers, as detected by the anti-VCAM-l MAb 4B9 (Fig. 3 A, lane b) . Preincubation of the stromal cultures with IL-1 resulted in a two-to threefold increase in expression of VCAM-1 (Fig. 3 A,  lane c) . In comparison, ICAM-1, a ligand for LFA-1 and Mac-1 was expressed at very low levels on resting cells but its expression was dramatically induced by incubation ofstromal monolayers with IL-1, as detected with anti-ICAM-1 MAb RRl/1 (Fig. 3 A, lanes dand e) . In contrast to VCAM-1 and ICAM-1, which were upregulated upon activation of stroma with IL-1, extracellular matrix proteins such as fibronectin and hemonectin were constitutively expressed and were not up-regulated by IL-l (data not shown).
To determine whether endogenous growth factors in resting stromal cells might cause basal VCAM-1 and ICAM-1 expres- (Table I) . The cDNA generated was tested for the presence of sequences corresponding to IL-3 (450 bp, lanes 2 and 3), IL-la (408 bp, lane 6) and IL-6 (636 bp, lane 9) by using PCR and specific primers. Lanes 5, 8, and 11 represent PCR reactions run with primers specific for IL-3, IL-lIa and IL-6 in the absence of stromal cell cDNA. Lanes 4, 7, and IO represent PCR reactions run with specific primers for IL-3, IL-a, and IL-6 in the presence of positive control cDNA supplied by the manufacturer. Products ofthe reactions were analyzed on a 1.5% agarose gels. Lanes I and 12 are the molecular size markers. sion, cDNA prepared from stromal cell mRNA was screened for IL-3, IL-1, and IL-6 by PCR analysis. As seen in Fig. 3 B, there were no detectable sequences specific for IL-3 (lanes 2 and 3) or IL-6 (lane 9). However, mRNA specific for IL-1 (Fig. 2 B, lane 6 ) was detected. These results were further confirmed by indirect immunostaining using specific MAbs to human IL-a (data not shown). Thus a small amount of IL-a produced by resting stromal cells might be responsible for basal expression of VCAM-1 as seen in Fig. 3 (Fig. 4 A) . Induction of VCAM-1 expression by pretreatment of stromal cells with IL-1 resulted in increased CD34hi cell adhesion, which was also significantly inhibited by anti-a4 (-40%, P < 0.05) and anti-VCAM-MAbs (Fig. 4 A) . Maximal adhesion as seen in Fig. 4 A, represented 28% of total cells added, or 35% ofVLA-4+ cells. In a separate experiment, adhesion to stroma was somewhat lower, as 6% of the total cells, or 12% of the VLA-5+ cells were adherent (Fig. 4 B) . As shown, preincubation with an anti-a5 antibody caused significant (P < 0.05) inhibition (50%) of the binding of CD34h' cells (Fig. 4 B). Additional experiments showed that an anti-# I MAb inhibited adhesion ofCD34hi cells to stroma by 63±10% (Table II) . These results suggest that VCAM-1 and fibronectin on stromal cells and VLA-4 and VLA-5 on CD34hI cells may play a role in the adhesion ofCD34hI marrow progenitors to stroma. In addition to f,, integrins, 2 integrins expressed on CD34hi cells are also involved, based on partial blocking ofCD34hi adhesion to stroma an anti-32 antibody (Fig. 4 C) . Inhibition by anti-f2 was more obvious (35%) when stromal cells were pretreated with IL-1. Together these results suggest that at least three different integrins, and multiple adhesion pathways are important for CD34Ii attachment to certain stromal cells in the marrow microenvironment.
Adhesion ofvarious leukocyte cell lines to stromal cells. To confirm and extend the finding that stromal cell monolayers support VLA-4/VCAM-1-dependent cell adhesion, leukocyte cell lines in the myeloid and lymphoid lineages were analyzed. A human IL-3-dependent cell line KMT-2, which expresses CD34, was inhibited by anti-VLA-4 and anti-VCAM-antibodies, only when the stromal monolayers were preincubated with IL-1. Thus, these cells must utilize other adhesion path- incorporated radioactivity measured in a y-counter. **Adhesion was significantly inhibited, P < 0.05 according to the Student's two-tailed t test. *Inhibition was observed, but was not quite low enough to meet P < 0.05 confidence level.
ways to interact with resting stroma (Fig. 5 A) . Other myeloid (U937) and lymphoid cell lines (preB Ramos, Nalm 6; T cell Jurkat) showed different degrees of adhesion to resting and activated stromal monolayers, and each was partly or almost completely inhibited by anti-VLA-4 and anti-VCAM-l antibodies (Fig. 5, B-E ). In addition, as seen in the case ofCD34h progenitors, monoclonal antibodies to the ,2 integrins also inhibited binding (by 5-10%) of some of the leukocyte cell lines to IL-l-activated stromal cells (data not shown). Adhesion ofCD34hi cells to purified proteins. Indirect evidence-in Fig. 4 strongly suggested that VLA-4/VCAM-1 and VLA-5/fibronectin pathways are important for CD34'I cell attachment to stromal cells. To provide a more direct evaluation of the function of VLA-4 and VLA-5 on CD341' cells, their adhesion to optimal concentrations of purified ligands sVCAM, FN-40, and intact fibronectin was tested. The antia4 MAb HP2/ 1 completely inhibited adhesion ofCD34hi cells to sVCAM (Fig. 6 A) . The anti-a4 MAb also substantially inhibited adhesion of CD34h' cells to the FN-40 fragment of fibronectin coated onto microtiter wells (Fig. 6 B) . Adhesion ofCD34Ii cells to intact fibronectin was markedly inhibited by an anti-a5 MAb and also partially by anti-a4 MAb (Fig. 6 C) . In Fig. 6, A, B , and C, adherent cells represented 13%, 14%, and 44% of the total population, respectively. Considering only VLA-4+ cells, adherent cells represented 17%, 18%, and 55%, respectively (Fig. 6, A, B, and C) . Of the VLA-5+ cells, 87% bound to fibronectin (Fig. 6 C) (58) (59) (60) , different cell populations are being studied using different in vivo and in vitro assays.
The VLA-4/VCAM-1 adhesion pathway has been implicated in important physiological processes involving migration and localization ofimmune cells (24, 26, 27, (61) (62) (63) (64) (65) (66) and some tumor cells (23, 67) . In the present study we have established that this adhesion pathway also plays a role in mediating adhe- Although the role of diffusible and stroma-derived growth factors in stem cell regulation has been extensively studied (69) (70) (71) (72) (73) (74) , the functions of adhesion molecules remain to be defined. The influence of fibronectin on proliferation and differentiation of erythroid cells has been documented (75, 76) . Adhesion of CD4-CD8 -thymocytes to thymic stromal cells through FN-FN receptor interaction is known to be critical for their differentiation (77 Disruption ofnormal adhesion pathways between stem and stromal cells has been implicated as a critical factor in pathogenesis of chronic myeloid leukemia (81, 82) . Furthermore, after chemotherapy and/or total body irradiation, the observed extravascation of stem cells into peripheral blood (83) 
